Isomorphic Labs Unveils Drug Design Engine
andsoitis · hn · 2026-07-18
Isomorphic Labs has published an article introducing its drug design engine, emphasizing it as a new phase beyond AlphaFold.
The core message is that the team is no longer limited to protein structure prediction. Instead, AI is being applied to drug design and molecular optimization, integrating structures, biology, and design processes to target a more complete R&D workflow. The article describes this engine as a new frontier, framing the transition from "seeing structures" to "designing molecules."
More from Companies & People
- Investor argues Palantir-Nvidia partnership should slash Anthropic's IPO valuation — pdamodaran · 2026-09-11
- PyTorch Day Korea 2026 launches first offline conf, CFP closes Sept 13 — PyTorch · 2026-09-11
- Class action accuses Anthropic of overselling Claude subscriptions with deceptive usage multipliers — The Decoder · 2026-09-11
- AI post-training and evals jobs pay up to $850K, with median offers at $210K–$325K — FinanceYF5 · 2026-09-11
- Only a 4-day window: timeline casts doubt on OpenAI's independent math result claim — gleech · 2026-09-11
- 89% of firms use AI, only 6% see significant ROI — the busywork illusion — mikeflache · 2026-09-11